Stock LFMD LIFEMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.95 USD +10.44% Intraday chart for LifeMD, Inc. +23.20% +44.15%
Apr. 23 BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating MT
Mar. 12 Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
LIFEMD, INC. Stock LifeMD, Inc.
+44.15% 482M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
C-
SECTRA AB Stock Sectra AB
+22.93% 3.89B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M -
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LFMD Stock
  4. Ratings LifeMD, Inc.